Genetic determinants of electrocardiographic P-wave duration and relation to atrial fibrillation
Weng, Lu Chen; Hall, Amelia Weber; Choi, Seung Hoan; Jurgens, Sean J.; Haessler, Jeffrey; Bihlmeyer, Nathan A.; Grarup, Niels; Lin, Honghuang; Teumer, Alexander; Li-Gao, Ruifang; Yao, Jie; Guo, Xiuqing; Brody, Jennifer A.; Müller-Nurasyid, Martina; Schramm, Katharina; Verweij, Niek; van den Berg, Marten E.; van Setten, Jessica; Isaacs, Aaron; Ramírez, Julia; Warren, Helen R.; Padmanabhan, Sandosh; Kors, Jan A.; de Boer, Rudolf A.; van der Meer, Peter; Sinner, Moritz F.; Waldenberger, Melanie; Psaty, Bruce M.; Taylor, Kent D.; Völker, Uwe; Kanters, Jørgen K.; Li, Man; Alonso, Alvaro; Perez, Marco V.; Vaartjes, Ilonca; Bots, Michiel L.; Huang, Paul L.; Heckbert, Susan R.; Lin, Henry J.; Kornej, Jelena; Munroe, Patricia B.; van Duijn, Cornelia M.; Asselbergs, Folkert W.; Stricker, Bruno H.; van der Harst, Pim; Kääb, Stefan; Peters, Annette; Sotoodehnia, Nona; Rotter, Jerome I.; Mook-Kanamori, Dennis O.
(2020) Circulation: Genomic and Precision Medicine, volume 13, issue 5, pp. 387 - 395
(Article)
Abstract
BACKGROUND: The P-wave duration (PWD) is an electrocardiographic measurement that represents cardiac conduction in the atria. Shortened or prolonged PWD is associated with atrial fibrillation (AF). We used exome-chip data to examine the associations between common and rare variants with PWD. METHODS: Fifteen studies comprising 64440 individuals (56943 European, 5681
... read more
African, 1186 Hispanic, 630 Asian) and ≈230000 variants were used to examine associations with maximum PWD across the 12-lead ECG. Meta-analyses summarized association results for common variants; gene-based burden and sequence kernel association tests examined low-frequency variant-PWD associations. Additionally, we examined the associations between PWD loci and AF using previous AF genome-wide association studies. RESULTS: We identified 21 common and low-frequency genetic loci (14 novel) associated with maximum PWD, including several AF loci (TTN, CAND2, SCN10A, PITX2, CAV1, SYNPO2L, SOX5, TBX5, MYH6, RPL3L). The top variants at known sarcomere genes (TTN, MYH6) were associated with longer PWD and increased AF risk. However, top variants at other loci (eg, PITX2 and SCN10A) were associated with longer PWD but lower AF risk. CONCLUSIONS: Our results highlight multiple novel genetic loci associated with PWD, and underscore the shared mechanisms of atrial conduction and AF. Prolonged PWD may be an endophenotype for several different genetic mechanisms of AF.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Atrial fibrillation, Electrophysiology, Exome, Genetic, Genome-wide association studies, Population, genetic, atrial fibrillation, exome, electrophysiology, genome-wide association studies, population, Cardiology and Cardiovascular Medicine, Genetics(clinical), Genetics, Journal Article
ISSN: 2574-8300
Publisher: Lippincott Williams & Wilkins
Note: Funding Information: Dr Weng is supported by an American Heart Association (AHA) Postdoctoral Fellowship Award (17POST33660226). This work was supported by an AHA Strategically Focused Research Networks (SFRN) postdoctoral fellowship to Drs. Weng and Hall (18SFRN34110082). Funded in part by training grant (National Institute of General Medical Sciences) 5T32GM07814 (Dr Bihlmeyer) and R01HL116747 (Drs Arking and Bihlmeyer), and R01 HL111089 (Dr Arking). This material is based on work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1232825 (Dr Bihlmeyer). Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors(s) and do not necessarily reflect the views of the National Science Foundation. Additional support was provided by AHA grant 16EIA26410001 (Dr Alonso) and National, Heart, Lung and Blood Institute grant K24HL148521 (Dr Alonso). Dr Ramírez was supported by Medical Research Council grant MR/N025083/1, by the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) under REA grant agreement no. 608765 and from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 786833. Dr Sotoodehnia is supported by the following grants from the National Institutes of Health (NIH): R01HL141989, HL116747, and R01 HL111089, and by the Laughlin Family Fund. Dr Kornej was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 838259. Dr Benjamin is supported by NIH grants HHSN26818HV00006R; 75N92019D00031; R01HL092577; 1R01HL128914; and American Heart Association 18SFRN34110082. Dr Lunetta is supported by R01 HL092577, AHA 18SFRN34230127, and 18SFRN34150007. Dr Ellinor is supported by the Fondation Leducq (14CVD01), by grants from the NIH (1RO1HL092577, R01HL128914, K24HL105780), and by a grant from the AHA (18SFRN34110082). Dr Lubitz is supported by NIH grant 1R01HL139731 and AHA 18SFRN34250007. Additional funding and acknowledgments for each participating study are provided in the Data Supplement. Publisher Copyright: © 2020 American Heart Association, Inc.
(Peer reviewed)